Quick Cimzia launch overjoys UCB

UCB Pharma was delirious with glee when it managed to launch its new TNF inhibitor Cimzia for Crohn's disease just 48 hours after the FDA gave its blessing. As In Vivo notes, the joy is understandable: The agency's approval surprised skeptics and boosted shares by 20 percent immediately.

But the quick launch is significant for other reasons, too. Though they've become routine, it wasn't so long ago that the FDA was a mysterious, opaque agency, a sort of oracle from which approvals or denials might issue at any time. Then came user fees and deadlines, allowing drugmakers to prep their launches as the agency's action date approached, saving valuable patent-coverage time. Now, though, the understaffed agency has started missing more deadlines, and, infected with excess caution, second-guessing itself. So predictability is starting to suffer--and so might drugmakers' ability to plan ahead.

Not to mention new regulatory requirements, which dogged Cimzia through the approval process. But we'll let In Vivo tell the rest of that story.

- read the blog item

Related Articles:
UCB CEO plots strategy following Cimzia approval
FDA shocks UCB investors with Cimzia trial demand
Late-stage Cimzia trial for RA hits endpoints
UCB submits BLA for Cimzia

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.